{"id":"hycamtin","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Anemia","drugRate":"98%","severity":"common","organSystem":""},{"effect":"Neutropenia","drugRate":"83%","severity":"common","organSystem":""},{"effect":"Thrombocytopenia","drugRate":"81%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"33%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"22%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"21%","severity":"common","organSystem":""},{"effect":"Alopecia","drugRate":"20%","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"19%","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"14%","severity":"common","organSystem":""},{"effect":"Asthenia","drugRate":"7%","severity":"common","organSystem":""},{"effect":"Pyrexia","drugRate":"5%","severity":"common","organSystem":""}],"contraindications":["Acute infectious disease","Anemia","Bone marrow depression","Breastfeeding (mother)","Diarrhea","Fibrosis of lung","Impaired renal function disorder","Interstitial lung disease","Interstitial pneumonia","Neutropenic colitis","Neutropenic disorder","Pregnancy, function","Radiation Therapy Involving the Lungs","Severe Bone Marrow Depression","Thrombocytopenic disorder"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Myelosuppression","drugRate":"","severity":"serious"},{"effect":"Interstitial Lung Disease (ILD)","drugRate":"","severity":"serious"},{"effect":"Gastrointestinal perforation","drugRate":"","severity":"serious"},{"effect":"Anaphylactoid reactions","drugRate":"","severity":"serious"},{"effect":"Angioedema","drugRate":"","severity":"serious"},{"effect":"Allergic manifestations","drugRate":"","severity":"serious"},{"effect":"Mucosal inflammation","drugRate":"","severity":"serious"},{"effect":"Hematologic toxicity deaths","drugRate":"1.9%","severity":"serious"},{"effect":"Non-hematologic toxicity deaths","drugRate":"0.7%","severity":"serious"}]},"trials":[],"_chembl":{"chemblId":"CHEMBL1607","moleculeType":"Small molecule","molecularWeight":"457.91"},"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Hycamtin","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:18:13.684066+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:18:21.839888+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hycamtin","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:18:22.637062+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA topoisomerase I inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:18:23.179276+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1607/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:18:23.099653+00:00"}},"offLabel":[],"timeline":[],"_dailymed":{"setId":"b23b46f5-c276-47f5-8bbd-940680b3f579","title":"HYCAMTIN (TOPOTECAN) CAPSULE [SANDOZ INC]"},"ecosystem":[],"mechanism":{"target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 4, ATP-binding cassette sub-family G member 2"},"_scrapedAt":"2026-03-28T01:42:24.368Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:18:25.159816+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Malignant tumor of cervix","diseaseId":"malignant-tumor-of-cervix","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Malignant tumor of ovary","diseaseId":"malignant-tumor-of-ovary","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Small cell carcinoma of lung","diseaseId":"small-cell-carcinoma-of-lung","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06459180","phase":"PHASE3","title":"A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-07-24","conditions":"Cervical Cancer","enrollment":686},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":"Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":478},{"nctId":"NCT03289910","phase":"PHASE2","title":"Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-24","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia","enrollment":25},{"nctId":"NCT05353439","phase":"PHASE1","title":"Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-07-27","conditions":"Extensive Stage Lung Small Cell Carcinoma, Limited Stage Lung Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma","enrollment":18},{"nctId":"NCT07437963","phase":"PHASE1, PHASE2","title":"Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-05-01","conditions":"Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma","enrollment":76},{"nctId":"NCT03896503","phase":"PHASE2","title":"Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-30","conditions":"Extensive Stage Lung Small Cell Carcinoma, Extrapulmonary Small Cell Neuroendocrine Carcinoma, Limited Stage Lung Small Cell Carcinoma","enrollment":104},{"nctId":"NCT04994977","phase":"PHASE1","title":"Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2023-05-04","conditions":"Atypical Choroid Plexus Papilloma, Choroid Plexus Carcinoma","enrollment":1},{"nctId":"NCT02298348","phase":"PHASE1","title":"Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2015-10-08","conditions":"Neuroblastoma","enrollment":18},{"nctId":"NCT07214779","phase":"PHASE3","title":"Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression","status":"RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-12-09","conditions":"Ovarian Cancer","enrollment":466},{"nctId":"NCT07213804","phase":"PHASE3","title":"A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-10-22","conditions":"Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms","enrollment":1080},{"nctId":"NCT07286266","phase":"PHASE3","title":"A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-06-24","conditions":"Ovarian Neoplasms","enrollment":450},{"nctId":"NCT06801834","phase":"PHASE3","title":"Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2025-04-04","conditions":"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","enrollment":695},{"nctId":"NCT05990738","phase":"PHASE1","title":"DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-02-14","conditions":"Small Cell Lung Carcinoma (SCLC)","enrollment":69},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT07218146","phase":"PHASE3","title":"A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)","status":"RECRUITING","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2025-11-30","conditions":"Small-cell Lung Cancer","enrollment":480},{"nctId":"NCT06449209","phase":"PHASE2","title":"Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2024-08-05","conditions":"Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer","enrollment":110},{"nctId":"NCT05153239","phase":"PHASE3","title":"Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"PharmaMar","startDate":"2022-07-22","conditions":"Relapsed Small Cell Lung Cancer","enrollment":705},{"nctId":"NCT07099898","phase":"PHASE3","title":"A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-11","conditions":"Neoplasms, Lung","enrollment":420},{"nctId":"NCT02502266","phase":"PHASE2, PHASE3","title":"Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-05-03","conditions":"Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma","enrollment":582},{"nctId":"NCT04739800","phase":"PHASE2","title":"Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-10","conditions":"Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma","enrollment":120},{"nctId":"NCT06619236","phase":"PHASE3","title":"Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2025-02-07","conditions":"Platinum-resistant Ovarian Cancer","enrollment":530},{"nctId":"NCT06203210","phase":"PHASE3","title":"A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-05-21","conditions":"Small Cell Lung Cancer","enrollment":540},{"nctId":"NCT03126916","phase":"PHASE3","title":"Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2018-05-14","conditions":"Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma","enrollment":750},{"nctId":"NCT06942039","phase":"EARLY_PHASE1","title":"Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation","status":"RECRUITING","sponsor":"C17 Council","startDate":"2025-09-23","conditions":"CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor","enrollment":15},{"nctId":"NCT06647953","phase":"PHASE3","title":"Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2025-03-21","conditions":"Pleuropulmonary Blastoma","enrollment":110},{"nctId":"NCT04697628","phase":"PHASE3","title":"Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer","status":"COMPLETED","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2021-02-22","conditions":"Cervical Cancer","enrollment":502},{"nctId":"NCT04322318","phase":"PHASE2","title":"A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-10-19","conditions":"Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor","enrollment":256},{"nctId":"NCT07418749","phase":"PHASE3","title":"A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2026-03","conditions":"Recurrent Cervical Cancer, Metastatic Cervical Cancer","enrollment":398},{"nctId":"NCT05535166","phase":"PHASE2","title":"Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2022-12-20","conditions":"Medulloblastoma","enrollment":130},{"nctId":"NCT06937905","phase":"PHASE3","title":"Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2026-02-06","conditions":"Neuroendocrine Carcinoma","enrollment":129},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT05421897","phase":"PHASE1","title":"Rapid Administration Pilot for Infusing Dinutuximab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital Los Angeles","startDate":"2022-11-29","conditions":"Neuroblastoma","enrollment":11},{"nctId":"NCT07371663","phase":"PHASE1, PHASE2","title":"An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Beijing Tide Pharmaceutical Co., Ltd","startDate":"2025-12-03","conditions":"Solid Cancers, NSCLC (Advanced Non-small Cell Lung Cancer), Gastric (Stomach) Cancer","enrollment":266},{"nctId":"NCT07365241","phase":"PHASE3","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"AbbVie","startDate":"2026-04-14","conditions":"Small Cell Lung Cancer","enrollment":531},{"nctId":"NCT01175356","phase":"PHASE1","title":"Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-12-21","conditions":"Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma","enrollment":99},{"nctId":"NCT01231906","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2010-11-24","conditions":"Localized Extraskeletal Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor of Bone, Peripheral Primitive Neuroectodermal Tumor of Soft Tissues","enrollment":642},{"nctId":"NCT06930755","phase":"PHASE1","title":"Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer","status":"RECRUITING","sponsor":"Nerviano Medical Sciences","startDate":"2026-01-31","conditions":"Ovarian Cancer","enrollment":24},{"nctId":"NCT07218809","phase":"PHASE3","title":"AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-29","conditions":"Epithelial Ovarian Cancer","enrollment":1100},{"nctId":"NCT02813135","phase":"PHASE1, PHASE2","title":"European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2016-08-03","conditions":"Pediatric Cancer","enrollment":472},{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT06666712","phase":"PHASE1","title":"Chronic CED of TPT for Recurrent Malignant Glioma","status":"RECRUITING","sponsor":"Jeffrey N. Bruce","startDate":"2026-03","conditions":"Brain Tumor, Recurrent, Malignant Glioma (WHO Grade III or IV), IDH1/IDH2 Mutation","enrollment":6},{"nctId":"NCT07334301","phase":"PHASE1, PHASE2","title":"A Multi-Arm, Platform Trial For Relapsed Neuroblastoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2024-11-11","conditions":"Relapsed Neuroblastoma","enrollment":160},{"nctId":"NCT06161025","phase":"PHASE2, PHASE3","title":"A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2024-02-27","conditions":"Solid Cancer","enrollment":860},{"nctId":"NCT07321912","phase":"PHASE2","title":"Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma","status":"NOT_YET_RECRUITING","sponsor":"Milton S. Hershey Medical Center","startDate":"2026-04-01","conditions":"Osteosarcoma, Ewing Sarcoma, Ewing Sarcoma Metastatic","enrollment":406},{"nctId":"NCT06861244","phase":"PHASE2","title":"Embryonal Tumor With Multilayered Rosettes","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-03-06","conditions":"Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos","enrollment":70},{"nctId":"NCT01757626","phase":"PHASE1, PHASE2","title":"Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-12","conditions":"Neuroblastoma","enrollment":186},{"nctId":"NCT05740566","phase":"PHASE3","title":"Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2023-05-31","conditions":"Small Cell Lung Cancer (SCLC)","enrollment":509},{"nctId":"NCT07189455","phase":"PHASE3","title":"Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Suzhou Zelgen Biopharmaceuticals Co.,Ltd","startDate":"2025-12-12","conditions":"Small-cell Lung Cancer","enrollment":420},{"nctId":"NCT03651206","phase":"PHASE2, PHASE3","title":"Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib","status":"RECRUITING","sponsor":"ARCAGY/ GINECO GROUP","startDate":"2020-07-15","conditions":"Ovarian Carcinosarcoma, Endometrial Carcinosarcoma","enrollment":138},{"nctId":"NCT06855069","phase":"PHASE3","title":"HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"Hansoh BioMedical R&D Company","startDate":"2025-03-13","conditions":"Ovarian Cancer","enrollment":468},{"nctId":"NCT02364713","phase":"PHASE2","title":"MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-03-13","conditions":"Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma","enrollment":17},{"nctId":"NCT05521984","phase":"PHASE1","title":"Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-04-03","conditions":"Pediatric Brain Tumor, Pediatric Solid Tumor","enrollment":20},{"nctId":"NCT06425419","phase":"PHASE1","title":"The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts Eye and Ear Infirmary","startDate":"2026-04-01","conditions":"Proliferative Vitreoretinopathy, Proliferative Vitreo-Retinopathy, Rhegmatogenous Retinal Detachment","enrollment":50},{"nctId":"NCT04681417","phase":"PHASE2, PHASE3","title":"Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2021-03-25","conditions":"Retinoblastoma","enrollment":225},{"nctId":"NCT01857934","phase":"PHASE2","title":"Therapy for Children With Advanced Stage Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-07-05","conditions":"Neuroblastoma","enrollment":153},{"nctId":"NCT07230626","phase":"PHASE3","title":"SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC Megalith Biopharmaceutical Co.,Ltd.","startDate":"2025-11-20","conditions":"Cervical Cancer","enrollment":412},{"nctId":"NCT02101788","phase":"PHASE2, PHASE3","title":"Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-04-11","conditions":"Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma, Ovarian Serous Adenocarcinoma","enrollment":260},{"nctId":"NCT05613088","phase":"PHASE2","title":"A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2023-02-01","conditions":"Neoplasms, Ovarian","enrollment":106},{"nctId":"NCT05429502","phase":"PHASE1","title":"Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-12-27","conditions":"Neuroblastoma","enrollment":12},{"nctId":"NCT03786783","phase":"PHASE2","title":"Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-03-04","conditions":"Ganglioneuroblastoma, High Risk Neuroblastoma","enrollment":42},{"nctId":"NCT02514447","phase":"PHASE1, PHASE2","title":"Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy","status":"COMPLETED","sponsor":"G1 Therapeutics, Inc.","startDate":"2015-10-05","conditions":"Small Cell Lung Cancer","enrollment":123},{"nctId":"NCT05870748","phase":"PHASE2, PHASE3","title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","status":"TERMINATED","sponsor":"Sutro Biopharma, Inc.","startDate":"2023-07-12","conditions":"Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":600},{"nctId":"NCT01012817","phase":"PHASE1, PHASE2","title":"Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-11-03","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma","enrollment":88},{"nctId":"NCT03107988","phase":"PHASE1","title":"NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)","status":"COMPLETED","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2017-09-05","conditions":"Neuroblastoma","enrollment":65},{"nctId":"NCT07171528","phase":"PHASE2","title":"Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-09-10","conditions":"Ovarian Cancer","enrollment":80},{"nctId":"NCT04908787","phase":"PHASE3","title":"A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer","status":"COMPLETED","sponsor":"Jiangsu Simcere Pharmaceutical Co., Ltd.","startDate":"2021-06-11","conditions":"Ovarian Cancer","enrollment":421},{"nctId":"NCT07145333","phase":"PHASE2, PHASE3","title":"Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair","startDate":"2025-08-12","conditions":"SCLC","enrollment":600},{"nctId":"NCT05874401","phase":"PHASE4","title":"Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan","status":"RECRUITING","sponsor":"Pharmacosmos A/S","startDate":"2023-10-18","conditions":"Extensive-stage Small-cell Lung Cancer","enrollment":302},{"nctId":"NCT04047251","phase":"PHASE1","title":"A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fujifilm Pharmaceuticals U.S.A., Inc.","startDate":"2019-11-14","conditions":"Advanced Solid Tumors, Merkel Cell Carcinoma","enrollment":96},{"nctId":"NCT00186888","phase":"PHASE3","title":"Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2005-04-07","conditions":"Retinoblastoma, Retinal Neoplasm","enrollment":107},{"nctId":"NCT03165292","phase":"PHASE2","title":"Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction","status":"TERMINATED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-10-01","conditions":"Very High Risk Neuroblastoma","enrollment":34},{"nctId":"NCT05092360","phase":"PHASE3","title":"Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)","status":"TERMINATED","sponsor":"Mural Oncology, Inc","startDate":"2022-01-10","conditions":"Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":456},{"nctId":"NCT04209855","phase":"PHASE3","title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression","status":"COMPLETED","sponsor":"AbbVie","startDate":"2019-12-31","conditions":"Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer","enrollment":453},{"nctId":"NCT07141771","phase":"PHASE1, PHASE2","title":"An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-12-31","conditions":"SCLC, Extensive Stage","enrollment":100},{"nctId":"NCT06994195","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2025-08-04","conditions":"Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer","enrollment":384},{"nctId":"NCT01931098","phase":"PHASE2","title":"Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-12-10","conditions":"Glioblastoma, Glioblastoma Multiforme, Gliosarcoma","enrollment":35},{"nctId":"NCT07106528","phase":"PHASE2, PHASE3","title":"Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-08","conditions":"Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive-stage Small Cell Lung Cancer (SCLC), Small Cell Lung Cancer ( SCLC )","enrollment":128},{"nctId":"NCT04947501","phase":"EARLY_PHASE1","title":"A Study of N9 Chemotherapy in Children With Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-06-22","conditions":"Neuroblastoma, Pediatric Cancer","enrollment":26},{"nctId":"NCT04106219","phase":"PHASE1","title":"A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-06-11","conditions":"Neuroblastoma","enrollment":71},{"nctId":"NCT07076095","phase":"PHASE2","title":"A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"SUNHO（China）BioPharmaceutical CO., Ltd.","startDate":"2025-08-01","conditions":"Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT04239092","phase":"PHASE1","title":"9-ING-41 in Pediatric Patients With Refractory Malignancies.","status":"TERMINATED","sponsor":"Actuate Therapeutics Inc.","startDate":"2020-06-05","conditions":"Refractory Cancer, Refractory Neoplasm, Cancer Pediatric","enrollment":40},{"nctId":"NCT00308165","phase":"PHASE1","title":"Topotecan by Intracerebral Clysis for Recurrent Primary Malignant Brain Tumors","status":"COMPLETED","sponsor":"Jeffrey N. Bruce","startDate":"2004-03","conditions":"Brain Neoplasms, Primary Malignant","enrollment":16},{"nctId":"NCT06954246","phase":"PHASE3","title":"A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-06-04","conditions":"Small Cell Lung Cancer Extensive Stage","enrollment":450},{"nctId":"NCT02419495","phase":"PHASE1","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-26","conditions":"Advanced Malignant Solid Neoplasm, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":221},{"nctId":"NCT02354547","phase":"PHASE1","title":"A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors","status":"SUSPENDED","sponsor":"SynerGene Therapeutics, Inc.","startDate":"2014-12","conditions":"Neoplasm","enrollment":18},{"nctId":"NCT05101551","phase":"PHASE1","title":"Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy","status":"RECRUITING","sponsor":"Norman J. Lacayo","startDate":"2023-02-23","conditions":"Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT06990503","phase":"PHASE3","title":"SHR - A1811 Versus Chemotherapy for Platinum-resistant Recurrent Epithelial Ovarian Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-06-01","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT06972602","phase":"EARLY_PHASE1","title":"High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2025-04-01","conditions":"Retinoblastoma, Retinoblastoma, Recurrent","enrollment":10},{"nctId":"NCT03554473","phase":"PHASE1, PHASE2","title":"M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-11","conditions":"Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer","enrollment":37},{"nctId":"NCT02569957","phase":"PHASE2","title":"Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2015-10-02","conditions":"Malignant Ovarian Endometrioid Tumor, Malignant Ovarian Serous Tumor, Recurrent Fallopian Tube Carcinoma","enrollment":1},{"nctId":"NCT06500026","phase":"PHASE3","title":"A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2024-08-07","conditions":"Small Cell Lung Cancer","enrollment":714},{"nctId":"NCT06933394","phase":"PHASE2","title":"Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2025-05-01","conditions":"Neuroblastoma","enrollment":92},{"nctId":"NCT02487095","phase":"PHASE1, PHASE2","title":"Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2015-07-30","conditions":"Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma","enrollment":62},{"nctId":"NCT03475121","phase":"PHASE3","title":"Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma","status":"COMPLETED","sponsor":"Hospital JP Garrahan","startDate":"2018-01-01","conditions":"Unilateral Retinoblastoma","enrollment":84},{"nctId":"NCT03257267","phase":"PHASE3","title":"Study of Cemiplimab in Adults With Cervical Cancer","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-09-05","conditions":"Squamous Cell Carcinoma (SCC), Recurrent or Metastatic, Platinum-refractory Cervical Cancer","enrollment":608},{"nctId":"NCT05800587","phase":"PHASE2","title":"Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2023-02-22","conditions":"Lung Cancer, Small-cell Lung Cancer, Non Small Cell Lung Cancer","enrollment":280},{"nctId":"NCT06679634","phase":"PHASE2","title":"Retinoblastoma Phase II Expanded Access Clinical Trial","status":"RECRUITING","sponsor":"Targeted Therapy Technologies, LLC","startDate":"2025-02-21","conditions":"Retinoblastoma","enrollment":30},{"nctId":"NCT00588991","phase":"PHASE1","title":"Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2008-02-04","conditions":"Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia","enrollment":12},{"nctId":"NCT06828354","phase":"PHASE3","title":"A Study of SHR-A1811 in Subjects With Ovarian Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-03-13","conditions":"Ovarian Cancer","enrollment":300}],"_emaApprovals":[],"_faersSignals":[{"count":371,"reaction":"DEATH"},{"count":168,"reaction":"ANAEMIA"},{"count":161,"reaction":"NAUSEA"},{"count":160,"reaction":"WHITE BLOOD CELL COUNT DECREASED"},{"count":143,"reaction":"PLATELET COUNT DECREASED"},{"count":111,"reaction":"NEUTROPHIL COUNT DECREASED"},{"count":100,"reaction":"FATIGUE"},{"count":95,"reaction":"THROMBOCYTOPENIA"},{"count":89,"reaction":"DECREASED APPETITE"},{"count":88,"reaction":"NEUTROPENIA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"chemblId":"CHEMBL1607"},"formularyStatus":[],"_approvalHistory":[{"date":"20010803","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"20191008","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"20000118","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"20100326","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"19981130","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"20060614","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"20140228","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"20030509","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"20030226","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"20020306","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"19960528","type":"ORIG","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"20000210","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"20100326","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"20180905","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"20150602","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"19980204","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"20030311","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020671"},{"date":"20080905","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020981"},{"date":"20071011","type":"ORIG","sponsor":"SANDOZ","applicationNumber":"NDA020981"},{"date":"20180905","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020981"},{"date":"20140618","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020981"},{"date":"20100630","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020981"},{"date":"20111007","type":"SUPPL","sponsor":"SANDOZ","applicationNumber":"NDA020981"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":76,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Hycamtin","genericName":"Hycamtin","companyName":"North Eastern German Society of Gynaecological Oncology","companyId":"north-eastern-german-society-of-gynaecological-oncology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T01:18:25.159816+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}